發(fā)布時間：2018-02-22 03:24

  本文關(guān)鍵詞： 恩替卡韋 拉米夫定 HBeAg陽性 慢性乙型肝炎 HBeAg血清學轉(zhuǎn)換　出處：《中國臨床藥理學雜志》2015年14期 　論文類型：期刊論文

【摘要】：目的評價恩替卡韋治療e抗原陽性慢性乙型病毒性肝炎的臨床療效和安全性。方法 80例乙型肝炎e抗原(HBeAg)陽性慢性乙肝患者隨機分為恩替卡韋組(試驗組)和拉米夫定組(對照組),各40例。試驗組口服恩替卡韋片500 mg·d-1,對照組口服拉米夫定片100 mg·d-1,療程均為48周,比較2組患者在8,12,24,36,48周時谷丙轉(zhuǎn)氨酶(ALT)復常率、乙肝病毒DNA(HBV-DNA)低于下限率和HBe Ag血清學轉(zhuǎn)換率,且觀察治療期間2組患者的不良反應(yīng)。結(jié)果在第8,12周時,試驗組谷丙轉(zhuǎn)氨酶復常率為47.50%,65.00%,明顯高于對照組的25.00%,42.50%(P0.05);試驗組在各時間點HBV-DNA低于下限率均明顯高于對照組(P0.05);36,48周時,試驗組HBe Ag血清學轉(zhuǎn)換率為32.50%,35.00%,明顯高于對照組的12.50%,15.00%(P0.05)。2組不良反應(yīng)發(fā)生率差異無統(tǒng)計學意義(P0.05)。結(jié)論恩替卡韋治療HBe Ag陽性慢性乙肝療效好,不良反應(yīng)發(fā)生率低。
[Abstract]:Objective to evaluate the efficacy and safety of entecavir in treatment of e antigen positive chronic hepatitis B. Methods 80 cases of hepatitis B e antigen (HBeAg) positive chronic hepatitis B patients were randomly divided into entecavir group (experimental group) and lamivudine group (control group), 40 cases in each test group was treated with entecavir. Entecavir tablets 500 mg - D-1, control group was treated with the Lamivudine Tablets 100 mg - D-1, were treated for 48 weeks were compared between the 2 groups in 8,12,24,36,48 weeks Shigu alanine aminotransferase (ALT) normalization rate, DNA of hepatitis B virus (HBV-DNA) is lower than the lower limit rate and HBe rate of Ag seroconversion, and observe the adverse reactions during treatment in 2 groups the results. In 8,12 weeks, the experimental group ALT normalization rate was 47.50%, 65%, significantly higher than the control group 25%, 42.50% (P0.05); the experimental group at each time point HBV-DNA below the lower limit rate were significantly higher than the control group (P0.05); 36,48 weeks, group HBe Ag blood test The conversion rate of Qing school was 32.50%, 35%, which was significantly higher than 12.50% of the control group. There was no significant difference in the incidence of adverse reactions in 15% (P0.05).2 group (P0.05). Conclusion entecavir is effective in treating HBe Ag positive chronic hepatitis B, and the incidence of adverse reactions is low.

【作者單位】： 杭州市中醫(yī)院感染科;
【分類號】：R512.62

【參考文獻】

相關(guān)期刊論文 前2條

1 李敏基;;恩替卡韋初治慢性乙肝臨床療效分析[J];河北醫(yī)學;2010年03期

2 占勁松;;恩替卡韋治療慢性乙型肝炎60例3年臨床觀察[J];中西醫(yī)結(jié)合肝病雜志;2012年06期

【共引文獻】

相關(guān)期刊論文 前10條

1 姚偉明;徐東平;;抗HBV藥物靶位的研究進展[J];傳染病信息;2013年06期

2 ;Chinese Consensus on Antiviral Treatment of Chronic Hepatits B Patients with Nucleos(t)ide Analogues[J];Infection International(Electronic Edition);2013年02期

3 黃睿;郝迎迎;張俊;吳超;;拉米夫定聯(lián)合阿德福韋酯與恩替卡韋單藥對慢性乙型肝炎初治患者療效比較的Meta分析[J];重慶醫(yī)學;2014年01期

4 徐瑞芳;張志鋒;張曹庚;殷秋炯;劉紅;;恩替卡韋治療慢性乙型肝炎53例療效分析[J];蚌埠醫(yī)學院學報;2014年01期

5 科技部十二五重大專項聯(lián)合課題組專家;;乙型肝炎病毒相關(guān)肝硬化的臨床診斷、評估和抗病毒治療的綜合管理[J];實用肝臟病雜志;2014年02期

6 劉穎;樊蓉;陳簡;鄭志丹;廖寶林;梁攜兒;尹軍花;周秋根;孫劍;;慢性乙型肝炎病毒感染相關(guān)肝硬化患者的腎功能及危險因素分析[J];南方醫(yī)科大學學報;2014年04期

7 何文艷;安紅杰;徐金鳳;;恩替卡韋治療失代償期乙型肝炎肝硬化1例[J];中國肝臟病雜志(電子版);2014年01期

8 邢卉春;楊松;程丹穎;李s，

本文編號：1523524